Login to Your Account



Soliris credibility 'Regain' in MG as Alexion rolls out new results from phase III

By Randy Osborne
Staff Writer

Thursday, July 7, 2016

Martin Mackay, global head of R&D for Alexion Pharmaceuticals Inc., told BioWorld Today the firm is "very much in preparation mode" for talks with regulators about complement protein C5 binder Soliris for refractory generalized MG.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription